Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF1120 in FGFR1-amplified advanced non-small cell lung cancer
NL-OMON44999Phase 2Not yet recruiting
- Sponsor
- NVALT
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by NVALT. Primary endpoint: Progression-free survival. Planned start Jun 2014; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44999.